OptimizeRx Corporation OPRX 深 沪
等待开盘 04-01 09:30:00 美东时间
6.28
-0.180
-2.79%
华盛通- 最 高6.575
- 今 开6.52
- 成交量 38.99万股
- 最 低 6.19
- 昨 收 6.46
- 总市值 1.18亿
- 52周最高 22.25
- 市盈率 静 23.25
- 换手率 2.08%
- 52周最低 5.54
- 委 比 -36.12%
- 总股本 1875.96万
- 历史最高 99.178
- 量 比 0.50
- 振 幅 5.96%
- 历史最低 3.78
- 每 手 1
- 风险率 3.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty
OptimizeRx CEO warns of increased market volatility and uncertainty around MFN pricing. Lower 2026 forecasts due to cautious spending.
03-07 02:09
Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $17
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.
03-06 22:43
OptimizeRx shares are trading higher after the company reported better-than-expected Q4 financial results.
OptimizeRx shares are trading higher after the company reported better-than-exp...
03-06 05:23
OptimizeRx Lowers FY2026 Sales Guidance from $118.000M-$124.000M to $109.000M-$114.000M
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.000 million-$114.000 million.
03-06 05:03
OptimizeRx Q4 Adj. EPS $0.51 Beats $0.23 Estimate, Sales $32.200M Beat $31.100M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.23 by 124.67 percent. This is a 70 percent increase over earnings of $0.30 per share from the same
03-06 05:02
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag
Information Technology stocks lead the pack on quant strength in the latest screen, posting the highest average ratings among the sectors listed, while Health Care names rank at the bottom. The single...
03-02 12:48
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
OptimizeRx and Experian collaborate to enhance audience measurement and targeting in life sciences marketing. By integrating OptimizeRx's Micro-Neighborhood® data with Experian's identity graph, the partnership aims to improve transparency, accuracy, and scalability for DTC campaigns. This addresses fragmentation in identity resolution, reduces audience loss during onboarding, and provides a more complete view of campaign effectiveness. The solut...
01-07 13:00
OptimizeRx Announced Four New Partner Agreements That Expand Its In-Workflow Point-of-care Network, Fortify Its Long-term Competitive Position, And Increase Total National Provider Identifier Reach, Deal Terms Were Undisclosed
The newly executed agreements include:An exclusive, multi-year agreement with a high-demand e-prescribing (eRx) platform previously available only through a competitive networkA new partnership that extends the Company's
2025-12-17 17:33
